Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

Abstract Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on Id1 protein, a key factor involved in the KRAS oncogenic pathway, a...

Full description

Bibliographic Details
Main Authors: Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Molecular Cancer
Subjects:
KRAS-mutant lung adenocarcinoma
Trametinib
Id1
PD-1 inhibition
PD-L1
Proteasome
Online Access:https://doi.org/10.1186/s12943-024-01991-3

Internet

https://doi.org/10.1186/s12943-024-01991-3

Similar Items